Immatics Biotechnologies Current Debt
IMTXW Stock | USD 0.40 0.06 13.04% |
At this time, Immatics Biotechnologies' Short Term Debt is fairly stable compared to the past year. Interest Debt Per Share is likely to climb to 0.01 in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 10.8 M in 2024. . Immatics Biotechnologies' financial risk is the risk to Immatics Biotechnologies stockholders that is caused by an increase in debt.
Debt Ratio | First Reported 2010-12-31 | Previous Quarter (0.06) | Current Value (0.06) | Quarterly Volatility 0.00189702 |
Immatics |
Immatics Biotechnologies Financial Rating
immatics biotechnologies GmbH financial ratings play a critical role in determining how much Immatics Biotechnologies have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Immatics Biotechnologies' borrowing costs.Piotroski F Score | 5 | Healthy | View |
Beneish M Score | (5.84) | Unlikely Manipulator | View |
Immatics Biotechnologies Common Stock Shares Outstanding Over Time
Immatics Biotechnologies Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Immatics Biotechnologies' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Immatics Biotechnologies, which in turn will lower the firm's financial flexibility.Immatics Short Long Term Debt Total
Short Long Term Debt Total |
|
Understaning Immatics Biotechnologies Use of Financial Leverage
Understanding the structure of Immatics Biotechnologies' debt obligations provides insight if it is worth investing in it. Financial leverage can amplify the potential profits to Immatics Biotechnologies' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its cost of debt.
Last Reported | Projected for Next Year | ||
Short and Long Term Debt Total | 15.4 M | 10.8 M | |
Net Debt | -203.1 M | -213.2 M | |
Short Term Debt | 2.6 M | 2.7 M | |
Net Debt To EBITDA | 2.28 | 1.63 | |
Debt To Equity | (0.16) | (0.15) | |
Interest Debt Per Share | 0.01 | 0.01 | |
Debt To Assets | (0.06) | (0.06) | |
Total Debt To Capitalization | (0.17) | (0.18) | |
Debt Equity Ratio | (0.16) | (0.15) | |
Debt Ratio | (0.06) | (0.06) | |
Cash Flow To Debt Ratio | 4.57 | 4.06 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immatics Stock Analysis
When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.